Mice treated with CTLA-4 analogue (abatacept) had a reduction in femoral arteries atherosclerosis formation by 78%, also in murine models with a decreased expression of CTLA-4 membrane expression [247,248]; on the contrary, anti-CTLA-4 drugs are related to a plaque progression [249]. Here, CTLA4 is linked to atherosclerosis.